Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Oil Prices Fall as Iran Proposes New Deal Amid Ongoing U.S. Tensions 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Dollar Gains Slightly as Yen Volatility Continues After Japan Intervention 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Oil Prices Ease but Remain Set for Strong April Gains Amid Middle East Tensions 
Tokyo Inflation Slows Despite Energy Pressures and BOJ Policy Outlook 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Wall Street Mixed as Apple Earnings Boost Nasdaq and Oil Prices Ease 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Panama Defends Port Takeover Amid U.S.-China Tensions and Canal Dispute 
Asian Stocks Slip as Oil Prices Surge and Fed Signals Inflation Risks 
WTI Crude Oil Prices Rise Amid Iran Conflict Uncertainty 
Roche Diagnostics Korea revealed on Thursday, May 6, that it was granted approval for its Cobas test, a testing device used to detect severe acute respiratory syndrome coronavirus in laboratories.
Roche Diagnostic’s Cobas test - What it is
The Korea Herald reported that Roche Diagnostics Korea said that its Cobas test is not only effective in qualitative detection, but it can also differentiate between SARS-CoV-2, Influenza A, and Influenza B that may be present in nasal swab samples from individuals undergoing test for possible respiratory infection.
It was added that Roche’s Cobas SARS-CoV-2 test could also be utilized in the company’s automated molecular testing solutions, called the cobas 6800/8800 Systems. This has the capacity to furnish up to 96 results in as little as three hours, while the cobas 8800 System can give 960 results within eight hours.
Moreover, Roche’s cobas SARS-CoV-2 test boasts of more than 97% test sensitivity, thus allowing a more accurate identification if a virus is present or not. The company added that this can deliver results fast and accurately so that doctors can give the right diagnosis and prescribe the right treatment for the case.
Roche increased investment in S. Korea
Meanwhile, Roche Diagnostics AG is headquartered in Basel, Switzerland, and because it saw how South Korea responded to the COVID-19 pandemic, the company said it is investing more in Roche Korea due to its excellent response to the crisis.
“Compared to other countries, Korea has been controlling Covid-19 well,” Korea BioMed Review quoted Roche Diagnostics Korea’s general manager, Johnny Tse, as saying. “But it needs to prepare for the next stage. Most Covid-19 tests use PCR (polymerase chain reaction) but we may need antibody/antigen tests, rapid testing for crossing borders, or tests based on the progress of the disease (Covid-19).”
Roche made the right decision to invest more since the cobas SARS-CoV-2 test has finally been approved after efforts were exerted to produce this device that will help detect COVID-19 more accurately. Finally, Tse said that they are planning to continue investing in S. Korea and create more of the things that are needed in helping curb highly infectious diseases.
